Clinical and Translational Medicine (Apr 2022)
PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
- Huilai Zhang,
- Yaxiao Lu,
- Tingting Zhang,
- Qingpei Guan,
- Xiaoxuan Wang,
- Yixian Guo,
- Lanfang Li,
- Lihua Qiu,
- Zhengzi Qian,
- Shiyong Zhou,
- Wenchen Gong,
- Bin Meng,
- Xiubao Ren,
- Xianhuo Wang
Affiliations
- Huilai Zhang
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Yaxiao Lu
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Tingting Zhang
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Qingpei Guan
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Xiaoxuan Wang
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Yixian Guo
- Marvel Medical Laboratory Tianjin Marvelbio Technology Co., Ltd Tianjin China
- Lanfang Li
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Lihua Qiu
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Zhengzi Qian
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Shiyong Zhou
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- Wenchen Gong
- Department of Pathology Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Bin Meng
- Department of Pathology Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Xiubao Ren
- Department of Immunology/Biotherapy Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Xianhuo Wang
- Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Sino‐US Center for Lymphoma and Leukemia Research Tianjin China
- DOI
- https://doi.org/10.1002/ctm2.808
- Journal volume & issue
-
Vol. 12,
no. 4
pp. n/a – n/a
Abstract
No abstracts available.
